Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus capecitabine in recurrent/metastatic triple-negative breast cancer
ChiCTR-OIC-16009689Phase 2Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and capecitabine in breast cancer, sponsored by Cancer Hospital of Guangxi Medical University. Primary endpoint: Progression-free survival. Started Nov 2016; status: recruiting.
02
Drugs
Rivoceranibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-OIC-16009689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16009689.